Drug Profile


Alternative Names: EMD-68843; SB-659746A; Viibryd; Vilazodone hydrochloride

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck KGaA
  • Developer Allergan; moksha8 Pharmaceuticals
  • Class Amides; Antidepressants; Benzofurans; Indoles; Nitriles; Piperazines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase III Generalised anxiety disorder
  • Phase II Social phobia
  • No development reported Sexual function disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Sexual-function-disorders(In volunteers) in USA (PO, Tablet)
  • 01 Oct 2016 Forest Laboratories completes a phase III trial for Major depressive disorder (in adolescents) in USA (NCT01878292)
  • 01 Apr 2015 Forest initiates enrolment in a phase III trial for Major depressive disorder (In children, In adolescents, aged 7-17 years) in USA (NCT02436239)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top